Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | TGFbetaR2KO/IL13Ralpha2 CAR-T cells |
| Trade Name | |
| Synonyms | Autologous TGF-betaR2KO/IL13R-alpha2-CAR T Cells|TGFbRII-KO/IL-13Ra2 CAR T-cells |
| Drug Descriptions |
TGFbetaR2KO/IL13Ralpha2 CAR-T cells are autologous T-lymphocytes engineered with knockout of TGFbRII expression and to express a chimeric antigen receptor (CAR) targeting IL13Ra2, which potentially induce toxicity in IL13Ra2-expressing tumor cells (NCI Thesaurus). |
| DrugClasses | IL13RA2 Immune Cell Therapy 7 |
| CAS Registry Number | NA |
| NCIT ID | C213207 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| TGFbetaR2KO/IL13Ralpha2 CAR-T cells | TGFbetaR2KO/IL13Ralpha2 CAR-T cells | 0 | 1 |